Pain Management Drugs Market analysis by region and end user till 2025

The global market was valued at $ 53267.0 million in 2014 and is likely to garner $77255.7 million in 2025, growing at a CAGR of 3.87% during the forecast period according to Progressive Markets report, Global Pain Management Drugs Market - Size, Trend, Share, Opportunity Analysis, and Forecast, 2014-2025.

The pain management drugs market report provides a comprehensive review of the industry. It incorporates the market size and growth, market share analysis, key market segments, informed market outlook, market drivers and restraints, trends analysis, market statistics, and major competitors. The information in the report is a compilation of an extensive primary and secondary research with inputs from industry experts. The vital statistics, tables, and charts offered in the report add credibility to the research conclusions and findings. The report is a useful source of guidance for market players, investors, and new entrants as it helps them understand the overall market scenario for the historic period, 2014-2017 and the forecast period, 2018-2025.

The study allows market players and investors comprehend the market landscape with the help of important industry insights. Market landscape is provided in terms of the growth drivers, restraints and challenges, Porters Analysis, and market share analysis. The drivers and restraints help decide how to be a part of the markets growth. The Porters Analysis comprises the bargaining power of buyers, bargaining power of suppliers, the threat of substitutes, the threat of new entrants, and industry rivalry. This analysis helps assess the competition level in the industry. The market size helps gauge the combined revenue or unit volume of the industry. The market share analysis assists to identify the portion of sales of the companies providing solutions in the space.

The impact of the demand drivers and restraints of the market are analyzed in the pain management drugs market report. Factors such as the rise in incidences of chronic diseases, favorable regulatory scenario, and an increase in the geriatric population. In addition, advancements in the development of drugs as well as the presence of many untapped markets in the emerging economies provide opportunities for the growth of the market. Nonetheless, availability of alternative therapies, drug exploitation, and patent expiration of prescription drugs act as obstacles to the growth of the market.

The report provides an analysis of the various segments of the pain management drugs industry. The industry is segmented by type, indication, and geography. Based on type, the industry is bifurcated into NSAIDs, anesthetics, anticonvulsants, anti-migraine agents, antidepressants, opioids, and non-narcotic analgesics. The anesthetics segment garnered $5047.0 million in 2017 and is expected to reach $7387.6 million in 2025 during the forecast period. Based on indication, the market is classified as arthritic pain, neuropathic pain, cancer pain, chronic back pain, post-operative pain, migraine, and fibromyalgia. The cancer pain sector is likely to grow at a CAGR of 4.89% while the neuropathic pain is expected to grow at a CAGR of 4.69% during the forecast period. Geographically, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. The pain management drugs market analysis in North America is covered for the U.S., Canada, and Mexico. The market study in Europe covers Germany, France, UK, Italy, Spain, and the rest of Europe. In Asia-Pacific, the market is analyzed across Japan, China, Australia, India, South Korea, Taiwan, and the rest of Asia-Pacific. The market analysis in LAMEA covers Brazil, Saudi Arabia, Republic of South Africa, and the rest of LAMEA.

The report profiles the major market players operating in the pain management drugs industry. Besides providing an overview, the report also takes a close look at their financial and business segments and recent developments. The top market players in the global pain management drugs market include Novartis AG, Eli Lilly & Company, Abbott Laboratories, Endo Health Solutions, Inc., Purdue Pharma L.P., Pfizer, Inc., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Johnson & Johnson, and GlaxoSmithKline Plc.

The company makes use of primary corporate research and secondary inputs from trusted sources to build its own reference base. It maintains consistency in quality as it keeps itself updated with changes in market dynamics and gauging its net effect on global business trends.

Reach Us
Mr. Shriram Dighe
4th Floor, Unit 12, Marisoft III, 
West Wing, Marigold IT Park, 
Kalyani Nagar, Pune, Maharashtra 411014, 
India: +91 20 66346040 
Toll Free: + 1-888-906-9222 
help@progressivemarkets.com

This release was published on openPR.